Extracorporeal Membrane Oxygenation in the Context of the 2009 H1N1 Influenza A Pandemic

Abstract

Background:

Extracorporeal membrane oxygenation (ECMO) incorporates surgical techniques as adjuncts in the management of refractory respiratory dysfunction. For many years, its primary application was for support of neonatal infants in cardiorespiratory failure. As the 2009 H1N1 influenza A pandemic developed, more reports came in of severe respiratory dysfunction and even death that seemed to be occurring preferentially in younger adults. Centers with the capability began to use ECMO to salvage these patients.

Results:

The H1N1 virus is a subtype of influenza A. The hemagglutinin receptor binding is similar to that of the seasonal influenza virus, but 2009 H1N1 also binds to α2,3-linked receptors, which are found in the conjunctivae, distal airways, and alveolar pneumocytes. Influenza viruses elude host immune responses through drift and shift in the hemagglutinin (HA) and neuraminidase (NA) proteins. The incubation period ranges from 1–7 days. The majority of patients present with fever and cough, but a broad spectrum of clinical syndromes has been reported, and laboratory testing remains the mainstay of diagnosis. Most patients recover within a week without treatment. The H1N1 virus remains largely sensitive to the NA inhibitors but is resistant to the matrix protein-2 inhibitors. Extracorporeal membrane oxygenation provides continuous pulmonary (and sometimes cardiac) support and minimizes ventilator-induced lung injury. The potential for life-threatening complications is high. In 2009, in the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) randomized trial of ECMO, the overall survival rate was 63% in the ECMO group compared with 47% in the control group (p = 0.03). Similar studies have been reported from Australia and New Zealand, Canada, and France.

Conclusions:

Supportive management is continued along with ECMO. Antiviral drugs and antimicrobial agents should be given as appropriate, as should nutritional support. Volume management should be used. Ventilator settings should be reduced as ECMO support allows, with a goal of reducing airway pressures, ventilator rate, and FiO₂. Complications of ECMO are common. Bleeding, the most common, can result in death, especially if it occurs intracranially.

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. Update: influenza activity—United States, September 28, 2008–April 4, 2009, and composition of the 2009–10 influenza vaccine. MMWR Morb Mortal Wkly Rep, 2009; 58:369–374.

Centers for Disease Control and Prevention. Swine Influenza A (H1N1) infection in two children—Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep, 2009; 58:400–402.

Centers for Disease Control and Prevention. Update: Infections with a swine-origin influenza A (H1N1) virus—United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep, 2009; 58:431–433.

Centers for Disease Control and Prevention. Update: novel influenza A (H1N1) virus infections—Worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep, 2009; 58:453–458.

Smith

, Vijaykrishna

, Bahl

et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature, 2009; 459:1122–1125.

Childs

, Palma

, Wharton

et al. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol, 2009; 27:797–799.

Shinya

, Ebina

, Yamada

et al. Avian flu: Influenza virus receptors in the human airway. Nature, 2006; 440:435–436.

Chan

, Chan

, Yu

et al. Tropism and innate host responses of the 2009 pandemic H1N1 influenza virus in ex vivo and in vitro cultures of human conjunctiva and respiratory tract. Am J Pathol, 2010; 176:1828–180.

Maines

, Jayaraman

, Belser

et al. Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice. Science, 2009; 325:484–748.

10.

Mandell

, Bennett

, Dolin

. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Sixth. Philadelphia: Elsevier Churchill Livingstone, 2005.

11.

Kilbourne

. Influenza pandemics of the 20th century. Emerg Infect Dis, 2006; 12:9–14.

12.

Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep, 2009; 58:521–524.

13.

Hancock

, Veguilla

, Lu

et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med, 2009; 361:1945–1952.

14.

Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med, 2010; 362:1708–1719.

15.

Cauchemez

, Donnelly

, Reed

et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med, 2009; 361:2619–2627.

16.

Lessler

, Reich

, Cummings

et al. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med, 2009; 361:2628–2636.

17.

Yang

, Sugimoto

, Halloran

et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science, 2009; 326:729–733.

18.

Cao

, Li

X-W

, Mao

et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med, 2009; 361:2507–2517.

19.

Crum-Cianflone

, Blair

, Faix

et al. Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis, 2009; 49:1801–1810.

20.

Witkop

, Duffy

, Macias

et al. Novel influenza A (H1N1) outbreak at the U.S. Air Force Academy: Epidemiology and viral shedding duration. Am J Prevent Med, 2010; 38:121–126.

21.

Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med, 2009; 360:2605–2615.

22.

Human infection with new influenza A (H1N1) virus:. Clinical observations from Mexico and other affected countries, May 2009. Wkly Epidemiol Rec, 2009; 84:185–189.

23.

Clinical management of human infection with pandemic (H1N1) 2009: Revised guidance. Geneva: World Health Organization, November 2009. www.who.int/csr/resources/publications/swineflu/clinical_management/en/index.html. 2010 August 24.

24.

Fleury

, Burrel

, Balick Weber

et al. Prolonged shedding of influenza A (H1N1) virus: Two case reports from France 2009. Eur Surveill, 2009; 14:pii–19434.

25.

Blyth

, Iredell

, Dwyer

. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med, 2009; 361:2493.

26.

Hui

, Lee

, Chan

PKS

. Clinical management of pandemic 2009 influenza A (H1N1) infection. Chest, 2010; 137:916–925.

27.

Itoh

, Shinya

, Kiso

et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature, 2009; 460:1021–1025.

28.

World Health Organization Recommended Use of Antivirals. Pandemic (H1N1 2009 briefing note 8. www.who.int/csr/disease/swineflu/notes/h1n1_use_antivirals_20090820/en/index.html. 2010 August 25.

29.

World Health Organization. Clinical management of human infection with pandemic (H1N1 2009 revised guidance. www.who.int/csr/resources/publications/swineflu/clinical_management_h1n1.pdf. 2010 August 25.

30.

Kidd

, Down

, Nastouli

et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet, 2009; 374:1036.

31.

Gaur

, Bagga

, Barman

et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med, 2010; 362:88–89.

32.

Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec, 2009; 85:37–40.

33.

Centers for Disease Control and Prevention (CDC). Interim guidance on case definitions to be used for investigations of novel influenza A (H1N1) cases. www.dphss.guam.gov/docs/swine_flu/H1N1_Guidance/case%20def%20june%201.pdf. 2010 August 24.

34.

Dawood

, Hope

, Durrheim

et al. Estimating the disease burden of pandemic (H1N1) 2009 virus infection in Hunter New England, Northern New South Wales, Australia, 2009. PLoS One, 2010; 5:e9880.

35.

Grills

, Piers

, Barr

et al. A lower than expected adult Victorian community attack rate for pandemic (H1N1) 2009. Aust NZ J Public Health, 2010; 34:228–231.

36.

Gurav

, Pawar

, Chadha

et al. Pandemic influenza A (H1N1) 2009 outbreak in a residential school at Panchgani, Maharashtra, India. Indian J Med Res, 2010; 132:67–71.

37.

World Health Organization. Epidemiological summary of pandemic influenza A (H1N1) 2009 virus—Ontario, Canada, June 2009. Wkly Epidemiol Rec, 2009; 84:485–491.

38.

France

, Jackson

, Schrag

et al. Household transmission of 2009 influenza A (H1N1) virus after a school-based outbreak in New York City, April–May 2009. J Infect Dis, 2010; 201:984–992.

39.

Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec, 2009; 84:481–484.

40.

Louie

, Acosta

, Winter

et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA, 2009; 302:1896–1902.

41.

Jain

, Kamimoto

, Bramley

et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med, 2009; 361:1935–-1944.

42.

Dominguez-Cherit

, Lapinsky

, Macias

et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA, 2009; 302:1880–1887.

43.

The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med, 2009; 361:1925–1934.

44.

Kumar

, Zarychanski

, Pinto

et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA, 2009; 302:1872–1879.

45.

Centers for Disease Control and Prevention. Intensive-care patients with severe novel influenza A (H1N1) virus infection—Michigan, June 2009. MMWR Morb Mortal Wkly Rep, 2009; 58:749–752.

46.

O'Rourke

, Crone

, Vacanti

et al. Extracoporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: A prospective randomized study. Pediatrics, 1989; 84:957–963.

47.

Barlett

, Roloff

, Cornell

et al. Extracorporeal circulation in neonatal respiratory failure: A prospective randomized study. Pediatrics, 1985; 76:479–487.

48.

Bifano

, Hakanson

, Hingre

, Gross

. Prospective randomized controlled trial of conventional treatment or transport for ECMO in infants with persistent pulmonary hypertension (PPHN) Pediatr Res, 1992; 31:196A.

49.

Extracorporeal Life Support Organization. ECLS Registry Report. Ann Arbor: University of Michigan, January 2004.

50.

Goodman

, Green

. Extracorporeal life support for children with acute respiratory distress syndrome. Zwischenberger

, Steinhorn

, Bartlett

. ECMO: Extracorporeal Cardiopulmonary Support in Critical Care. Ann Arbor, Mich: Extracorporeal Life Support Organization, 2000; 451–460.

51.

Zapol

, Snider

, Hill

et al. Extracorporeal membrane oxygenation in severe acute respiratory failure: A randomized prospective study. JAMA, 1979; 242:2193–2196.

52.

Morris

, Wallace

, Menlove

et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO₂ removal for adult respiratory distress syndrome. Am J Respir Crit Care Med, 1994; 149:295–305.

53.

Peek

, Mugford

, Tiruvoipati

et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial. Lancet, 2009; 374:1351–1363.

54.

Lim

. The history of extracorporeal oxygenators. Anaesthesia, 2006; 61:984–995.

55.

Hill

, O'Brien

, Murray

et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome): Use of the Bramson membrane lung. N Engl J Med, 1972; 286:629–634.

56.

Bartlett

. The development of prolonged extracorporeal circulation. Arensman

, Cornish

. Extracorporeal Life Support. Boston: Blackwell Scientific Publications, 1993; 31–41.

57.

Gattinoni

, Pesenti

, Mascheroni

et al. Low-frequency positive-pressure ventilation with extracorporeal CO₂ removal in severe acute respiratory failure. JAMA, 1986; 256:8816.

58.

Sidebotham

, McGeorge

, McGuinness

et al. Extracorporeal membrane oxygenation for treating severe cardiac and respiratory disease in adults 1: Overview of extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth, 2009; 23:886–892.

59.

Brogan

, Thiagarajan

, Rycus

et al. Extracorporeal membrane oxygenation in adults with severe respiratory failure: A multi-center database. Intensive Care Med, 2009; 35:2105–2114.

60.

The Australia New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA, 2009; 302:1888–1895.

61.

Freed

, Henzler

, White

et al. Extracorporeal lung support for patients who had severe respiratory failure secondary to influenza A (H1N1) infection in Canada. Can J Anesth, 2010; 57:240–247.

62.

Roch

, Lepaul-Ercole

, Grisoli

et al. Extracorporeal membrane oxygenation for severe influenza A (H1N1) acute respiratory distress syndrome: A prospective observational comparative study. Intensive Care Med, 2010; 36:1899–1905.

63.

Berryman

. Extracorporeal membrane oxygenation in a Scottish intensive care unit. Nurs Crit Care, 2010; 15:262–268.

64.

Robertson

, Allen

, Konamme

et al. The successful use of extra-corporeal membrane oxygenation in the management of a pregnant woman with severe H1N1 2009 influenza complicated by pneumonitis and adult respiratory distress syndrome. Int J Obstet Anesth, 2010; 19:443–447.

65.

Oluyomi-Obi

, Avery

, Schneider

et al. Perinatal and maternal outcomes in critically ill obstetrics patients with pandemic H1N1 influenza A. J Obstet Gynaecol Can, 2010; 32:443–447.

66.

Peris

, Cianchi

, Biondi

et al. Extracorporeal life support for management of refractory cardiac or respiratory failure: Initial experience in a tertiary center. Scand J Trauma Resusc Emerg Med, 2010; 18:28.

67.

Buckley

, Sidebotham

, McGeorge

et al. Extracorporeal membrane oxygenation for cardiorespiratory failure in four patients with pandemic H1N1 2009 influenza virus and secondary bacterial infection. Br J Anaesth, 2010; 104:326–329.

68.

Grasselli

, Foti

, Patroniti

et al. A case of ARDS associated with influenza A–H1N1 infection treated with extracorporeal respiratory support. Minerva Anestesiol, 2009; 75:741–745.

69.

Kao

, Wang

, Chen

et al. The first case of severe novel H1N1 influenza successfully rescued by extracorporeal membrane oxygenation in Taiwan. J Formos Med Assoc, 2009; 108:894–898.

70.

Liong

, Lee

, Poon

et al. The first novel influenza A (H1N1) fatality despite antiviral treatment and extracorporeal membrane oxygenation in Hong Kong. Hong Kong Med J, 2009; 15:381–-384.

71.

Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection—Michigan. June 2009. MMWR Morb Mortal Wkly Rep, 2009; 58:749–752.

72.

Wildschut

, de Hoog

, Ahsman

et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One, 2010; 5:e10938.